Neuroacanthocytosis Syndromes

Neuroacanthocytosis Syndromes

No Results

No Results


Neuroacanthocytosis (NA) syndromes include combined features of acanthocytosis (ie, spiked red blood cells), chorea, orofacial tics, amyotrophy often with hyperCKemia, and normobetalipoproteinemia. NA has been described as inherited as an autosomal recessive disorder, as an autosomal dominant disorder, and as part of an X-linked disorder called McLeod syndrome (MLS). The autosomal recessive type, usually called chorea-acanthocytosis, is most common and was originally described by Levine and Critchley in the 1960s. [1, 2, 3] In 2001, the gene for this recessive type was characterized on chromosome 9. Since that year, rarer autosomal dominant disease forms with variable penetrance with or without chromosome 9 abnormalities have also been described. In all types, the neurologic course is progressive. Degeneration of the basal ganglia is a consistent feature of this disorder.

All of the syndromes under the NA umbrella are distinguished from the Bassen-Kornzweig syndrome, an autosomal recessive disorder of childhood in which abetalipoproteinemia and acanthocytosis occur along with steatorrhea, retinitis pigmentosa, and cerebellar ataxia.

Acanthocytosis has also been associated with the rare hypobetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP) syndrome, a disease of childhood akin to Hallervorden-Spatz disease and a defect in the gene for pantothenate kinase.

The array of clinical features in NA syndromes is complex. Not only are cases known in which neurologic features of classic adult and childhood acanthocytosis syndromes overlap, but adult forms have been well described in which lipid profiles more closely resemble those of Bassen-Kornzweig syndrome, as have adult forms that begin in childhood.

An adult NA syndrome due to an X-linked gene defect is known that largely excludes females.

NA syndromes that include parkinsonism, peripheral neuropathy, myopathy, seizures, and psychosis have been described.

Adult-type variants of NA have been associated with general medical disorders involving the heart and immune system.

In a detailed pathophysiological study, the well-described choreiform movement disorder of NA has been described coexisting with an associated peripheral neuropathy in a patient without acanthocytosis. See the image below.

For related information, see Neuroacanthocytosis.

The precise pathophysiology is not understood. Clues to the pathogenesis of the disorder arise from the observation that both the neurological and hematological systems are affected.

In the classic form of the disorder, central nervous system pathologic features include atrophy of the caudate and putamen and, to a lesser extent, the globus pallidus and substantia nigra. A cell loss of 90% in the striatum with astrocytic gliosis has been reported. In contrast to Huntington disease (HD), the major inherited choreiform disorder of adults, the cerebral cortex and corpus callosum are relatively spared. Additionally, the presence of acanthocytosis distinguishes NA from HD.

Defects in such disparate systems (ie, basal ganglia and erythrocytes) have led to the suggestion that a common neurohematological membrane defect is involved.

In 2001, a deletion mutation in the gene (now known as VPS13A) localized to chromosome band 9q21 was identified as the site for the defect generating the autosomal recessive form of NA. It has been determined that VPS13A encodes for a protein called chorein. Thus, patients with NA typically carrying this deletion mutation have a deficiency or even absence of chorein.

In 2005, based upon research involving several large French-Canadian families that presented with temporal lobe epilepsy, an expanded conceptualization of the molecular genetics of the autosomal recessive form NA was attained. Of family members in this research who presented with epilepsy, 70-80% had large deletions in the NA gene, now known as VPS13A, on chromosome 9. Some family members with no epilepsy but with milder features, such as tics and dysphagia for example, may be representative of heterozygous expression of the deletion, suggesting that variations in the VPS13A gene may lead to a dominant pattern of inheritance.

VPS13A may be involved in the control of protein cycling through the trans-Golgi network. It is broadly expressed and found in the brain, heart, skeletal muscle, and kidney.

The chorein deficiency has been also linked to upregulation of gephyrin and GABA(A) receptors.

Japanese researchers support this latter point by positing that the disorder in several families studied with the chorein defect and no seizures may have a dominant form of NA with incomplete penetrance. Further genetic variability is derived from the work of Walker who found an autosomal dominant NA family with a Huntington disease–like syndrome (HDL2) characterized by a defect in the junctophilin-3 gene and not the chorein gene. [4]

To further induce pathophysiological consternation, the McLeod syndrome (MLS) seen overwhelmingly in males has many features akin to the autosomal forms and is due to a completely separate abnormality featuring the following: (1) absent expression of Kx erythrocyte antigen, (2) weak expression of Kell glycoprotein antigens, (3) universally present hyperCKemia, and (4) X-linked inheritance. (Recently, the Kx protein has been shown to be neuronal, located mainly in intracellular compartments, suggesting a cell specific trafficking pattern.)

Variation in other systems in patients with NA syndromes reflects the possibility of genetic heterogeneity that is more wide ranging than what may be noted in the affected components of the red blood cell (RBCs) and striatum alone.

Indeed, Walker et al [5] noted in 2011 that in NA there exist several associated genetic loci in the 9q21 region. Many defects, including gene deletions and insertions, as well as missense, nonsense, and splicing, mutations, have been found spread over hundreds of kilobases of genomic DNA, making the authors’ case for exome sequencing to help with the diagnosis and genetic counseling, including carrier detection.

Other common sites of pathophysiological dysfunction are the spinal cord, muscles, and nerves.

Evidence of denervation with fasciculations has been noted intermittently on electromyography (EMG) and is consistent with motor neuron disease despite absence of anterior horn cell histopathology.

Neurogenic muscle atrophy on muscle biopsy is consistent with a possible insult affecting the anterior horn cells of the spinal cord or their axons, although a primary myopathy and even myositis also have been described.

The consistently noted increase in creatine phosphokinase (CPK) level may be due to a primary myopathy, neurogenic atrophy, or chorea. Chorein deficiency in NA has been implicated in the cause of the myopathy.

Nerve biopsy has revealed loss of large myelinated axons consistent with a distal axonopathy.

Both RBC membrane protein and lipid abnormalities have been described, notably in the critical band 3 protein layer (most recently in the Walker family) and in an abnormal composition of covalently bound fatty acids.

Antibodies to the GM1 ganglioside component of peripheral nerves have been described. This GM1 ganglioside is also present in RBC membranes and in the central nervous system. Decreases in GM3 and sialoparagloboside components of RBC membranes have been noted. These gangliosides are also present throughout the nervous system.

Many of the patients with MLS have cardiomyopathy or hemolytic anemia, features not as commonly noted in the autosomal cases.

Redman and Reid have commented on the complexity of the Kell blood group proteins whereby the Kell protein expressed via a gene on chromosome 7 interacts with the XK protein, strikingly absent in patients with MLS. [6] These proteins are preferentially expressed in erythroid tissue but are also present in lesser amounts in brain and skeletal and cardiac muscle. The Kell protein is essential in the activation of the endothelin system and is important in cell membrane integrity. The XK protein bound to it in a 2-protein complex may have a complementary role as a membrane transporter. Experimental evidence cited by van den Buuse and Webber suggests endothelins may be basal ganglia neurotransmitters. [7] Thus, the implication exists for a neurochemical tie to the NA syndromes, so often highlighted by basal ganglia dysfunction.

Jung et al have noted that in MLS, known disease-causing XK gene mutations comprised deletions, nonsense, or splice-site mutations, predicting absent or truncated XK protein devoid of the Kell-protein–binding site, but they found 2 brothers who had XK missense mutation without hematologic, neuromuscular, or cerebral involvement. However, despite their having the McLeod phenotype, the mutated XK protein seemed to be largely functional. [8]

Meanwhile, speaking to the great variability in MLS disorders, Wiethoff, in 2013 described a 70-year-old man of Greek origin with choreatic movements of the tongue and face, lower limb muscle weakness, peripheral neuropathy, elevated creatine phosphokinase (CPK), acanthocytosis, and hemolysis in the absence of Kell RBC antigens with an additional factor IX deficiency. Genetic testing for mutations in the 3 exons of the XK gene revealed a previously unreported hemizygous single base-pair frameshift deletion at exon 1 (c.229delC, p.Leu80fs). [9]

Bosman and De Franceschi have also summarized several studies of non-McLeod NA that have shown abnormalities in the aforementioned band 3 region. [10, 11] Changes in band 3 structure do not only lead to alterations in erythrocyte shape but also to altered anion transport characteristics and increased age-related autoimmunoreactivity, with anti-band 3 antibodies noted in patients with NA. Elaborating on this latter point, echinocytes are normally aging misshapen RBCs reported to have band 3 abnormalities as well.

Brain band 3 change is also tied to neuronal degeneration and has been linked generally to extrapyramidal movement disorders and axonal neuropathies.

These insights, though incompletely understood, suggest that the pathophysiology of all of the NA syndromes involves different gene abnormalities that can cause multisystem membrane defects. The common derangement is in the malformation of the RBC shape and the induction of various levels of central nervous system, neuromuscular, and cardiac dysfunction. Intriguingly is the prospect that some kind of accelerated senescence and autoimmune damage to both erythrocytes and nerve tissue holds a key in fully appreciating the triggering of acanthocytosis and neurodegeneration in NA syndromes.

Mindful that the neuroacanthocytotic MLS and a recently described non-McLeod NA family with no typical autosomal recessive gene NA defect are not due to a specific chorein protein abnormalities, it is still extremely important to expand our knowledge of chorein, the protein specifically linked to most cases of NA. Chorein is normally present in man. Dobson-Stone suggests the CHAC or chorein gene locus is abnormal in many ways to induce NA by either not producing gene product or yielding a truncated nonfunctional protein. [12]

However, beyond being involved in protein-protein trafficking, how this protein leads to malconfigured erythrocytes and the array of neuropathological and clinical signs of NA is not clear. A patient has been described with chorein deficiency in red blood cells in the absence of acanthocytosis. [13] Further confounding the issue, deficiency of erythroid 4.1R protein has been described in patients with NA. This protein is distinct from chorein and essential for maintaining erythrocyte shape and mechanical properties of the membrane, such as deformability and stability.

Many issues in NA and MLS are still unresolved, not the least of which is why these 2 disorders present syndromes that are so similar, despite showing distinct genetic defects. Why the genetic defects in NA and MLS induce hematologic, cardiac, and neurologic abnormalities is also not clear. In MLS, Walker and Danek note that different Kell mutations may have different effects on the Kell gene product and thus may account for the variable phenotype in patients with MLS. Indeed, this variable mutation phenomenon may explain the differing clinical presentations in the autosomal gene NA syndromes (non-MLS). [14]

In 2011, De Franceschi et al [15] published a report that indicated erythrocyte membrane changes of NA patients are the result of altered Lyn kinase (LYN) activity, which is involved in modulating band 3 function on the RBC membrane. [16]

In 2012, De Franceschi et al [17] went beyond the LYN identification and attributed NA acanthocyte genesis to a very restricted group of highly interconnected kinases, including LYN and ABL1, ABL2, AURKA, CDK5, EPHB2, EPHB4, FYN, MAP4K2, MAPK14, PDPK1, RPS6KA3, TGFBR1, and TTN, that regulate rho small GTPase-mediated signaling, cytoskeleton network, erythropoiesis, and neurogenesis. The authors maintain that this network may represent a shared regulatory cluster of kinases whose alteration is most likely involved in the generation of the abnormal red blood cells that characterize NA. They also believe these same kinases might be responsible for acanthocyte generation in MLS.

United States

NA syndromes have been described in consanguineous and nonconsanguineous families of English and Puerto Rican descent.


NA syndromes have been described in American (USA), Chinese, Japanese, Malaysian, South-African black, Mexican, Brazilian, British, Spanish, Portuguese, Australian, Indian, Italian, Chilean, German, Turkish, Scandinavian, French-Canadian, French, and Thai [18] populations.

MLS has been described in multiple nationalities and races, with a Chinese patient first described with it in 2013 [19] and the first patients (a family) from India first described with the disorder in 2011. [20]

NA syndromes are often fatal.

A common cause of death is aspiration pneumonia due to movement disorder-induced impairment in swallowing.

Other causes of death include complications of cardiomyopathy and suicide as a result of depression or psychosis.

Morbidity is related specifically to the progressive movement disorder and muscle wasting.

Malnutrition is very common in many of these neurological syndromes.

Although the acanthocytosis often is noted spectacularly on peripheral blood smear (approaching 50% of patients) it usually is not associated with hemolytic anemia or other life-threatening hematological problems. However, hemolysis has been described, which can carry significant morbidity.

NA syndromes have been described in all races.

Overall, NA syndromes are more common in men (partly due to the McLeod syndrome types, which are X-linked and therefore almost exclusively found in men).

Presumed autosomal recessive NA is more common in males, with a male-to-female ratio as high as 70:30.

The adult-type NA syndromes usually begin in mid life (age 20-50 y). However, they also have been reported to occur in childhood.

Levine IM, Estes JW, Looney JM. Hereditary neurological disease with acanthocytosis. A new syndrome. Arch Neurol. 1968 Oct. 19(4):403-9. [Medline].

Critchley EM, Clark DB, Wikler A. Acanthocytosis and neurological disorder without betalipoproteinemia. Arch Neurol. 1968 Feb. 18(2):134-40. [Medline].

Peikert K, Danek A, Hermann A. Current state of knowledge in Chorea-Acanthocytosis as core Neuroacanthocytosis syndrome. Eur J Med Genet. 2017 Dec 16. [Medline].

Walker RH. Autosomal-dominant chorea-acanthocytosis: Report of a family and neuropathology In: Danek A, ed. Neuroacanthocytosis Syndromes. Springer. 2005.

Walker RH, Schulz VP, Tikhonova IR, Mahajan MC, Mane S, Arroyo Muniz M. Genetic diagnosis of neuroacanthocytosis disorders using exome sequencing. Mov Disord. 2011 Oct 28. [Medline].

Redman CM, Reid ME. The McLeod syndrome: an example of the value of integrating clinical and molecular studies. Transfusion. 2002 Mar. 42(3):284-6. [Medline].

van den Buuse M, Webber KM. Endothelin and dopamine release. Prog Neurobiol. 2000 Mar. 60(4):385-405. [Medline].

Jung HH, Hergersberg M, Kneifel S, et al. McLeod syndrome: a novel mutation, predominant psychiatric manifestations, and distinct striatal imaging findings. Ann Neurol. 2001 Mar. 49(3):384-92. [Medline].

Wiethoff S, Xiromerisiou G, Bettencourt C, Kioumi A, Tsiptsios I, Tychalas A. Novel single base-pair deletion in exon 1 of XK gene leading to McLeod syndrome with chorea, muscle wasting, peripheral neuropathy, acanthocytosis and haemolysis. J Neurol Sci. 2014 Feb 1. [Medline].

Bosman GM. Erythrocyte membrane abnormalities in neuroacanthocytosis: Evidence for a neuron-erythrocyte axis?. Danek A, ed. Neuroacanthocytosis Syndromes. Springer; 2005.

De Franceschi L, Corrocher R. Erythrocyte membrane anion exchange abnormalities in chorea-acanthocytosis: The band 3 network. Danek A, ed. Neuroacanthocytosis Syndromes. Springer. 2005.

Dobson-Stone C, Velayos-Baeza A, Filippone LA, et al. Chorein detection for the diagnosis of chorea-acanthocytosis. Ann Neurol. 2004 Aug. 56(2):299-302. [Medline].

Bayreuther C, Borg M, Ferrero-Vacher C, Chaussenot A, Lebrun C. [Chorea-acanthocytosis without acanthocytes]. Rev Neurol (Paris). 2010 Jan. 166(1):100-3. [Medline].

Walker RH, Danek A, Uttner I, Offner R, Reid M, Lee S. McLeod phenotype without the McLeod syndrome. Transfusion. 2007 Feb. 47(2):299-305. [Medline].

De Franceschi L, Tomelleri C, Matte A, Brunati AM, Bovee-Geurts PH, Bertoldi M. Erythrocyte membrane changes of chorea-acanthocytosis are the result of altered Lyn kinase activity. Blood. 2011 Nov 17. 118(20):5652-63. [Medline].

Lupo F, Tibaldi E, Matte A, Sharma AK, Brunati AM, Alper SL, et al. A new molecular link between defective autophagy and erythroid abnormalities in chorea-acanthocytosis. Blood. 2016 Dec 22. 128 (25):2976-2987. [Medline]. [Full Text].

De Franceschi L, Scardoni G, Tomelleri C, Danek A, Walker RH, Jung HH. Computational identification of phospho-tyrosine sub-networks related to acanthocyte generation in neuroacanthocytosis. PLoS One. 2012. 7(2):e31015. [Medline].

Kanjanasut N, Jagota P, Bhidayasiri R. The first case report of neuroacanthocytosis in Thailand: utilization of a peripheral blood smear technique for detecting acanthocytes. Clin Neurol Neurosurg. 2010 Jul. 112(6):541-3. [Medline].

Man BL, Yuen YP, Yip SF, Ng SH. The first case report of McLeod syndrome in a Chinese patient. BMJ Case Rep. 2013. 2013:[Medline].

Chakravarty A, Bhattacharya P, Banerjee D, Mukherjee S. Mcleod syndrome: Report of an Indian family with phenotypic heterogeneity. Ann Indian Acad Neurol. 2011 Jan. 14(1):53-5. [Medline]. [Full Text].

Troiano AR, Trevisol-Bittencourt PC. [Neuroacanthocytosis. A case report]. Arq Neuropsiquiatr. 1999 Jun. 57(2B):489-94. [Medline].

Bird TD, Cederbaum S, Valey RW, Stahl WL. Familial degeneration of the basal ganglia with acanthocytosis: a clinical, neuropathological, and neurochemical study. Ann Neurol. 1978 Mar. 3(3):253-8. [Medline].

Gross KB, Skrivanek JA, Carlson KC, Kaufman DM. Familial amyotrophic chorea with acanthocytosis. New clinical and laboratory investigations. Arch Neurol. 1985 Aug. 42(8):753-6. [Medline].

Neutel D, Miltenberger-Miltenyi G, Silva I, de Carvalho M. Chorea-acanthocytosis presenting as motor neuron disease. Muscle Nerve. 2012 Feb. 45(2):293-5. [Medline].

Orr HT. FTD and ALS: genetic ties that bind. Neuron. 2011 Oct 20. 72(2):189-90. [Medline].

Jung HH, Haker H. Schizophrenia as a manifestation of X-linked Mcleod-Neuroacanthocytosis syndrome. J Clin Psychiatry. 2004 May. 65(5):722-3. [Medline].

Bruneau MA, Lespérance P, Chouinard S. Schizophrenia-like presentation of neuroacanthocytosis. J Neuropsychiatry Clin Neurosci. 2003. 15(3):378-80. [Medline].

Dotti MT, Battisti C, Malandrini A, et al. McLeod syndrome and neuroacanthocytosis with a novel mutation in the XK gene. Mov Disord. 2000 Nov. 15(6):1282-4. [Medline].

Nicholl DJ, Sutton I, Dotti MT, Supple SG, Danek A, Lawden M. White matter abnormalities on MRI in neuroacanthocytosis. J Neurol Neurosurg Psychiatry. 2004 Aug. 75(8):1200-1. [Medline].

Gradstein L, Danek A, Grafman J, Fitzgibbon EJ. Eye movements in chorea-acanthocytosis. Invest Ophthalmol Vis Sci. 2005 Jun. 46(6):1979-87. [Medline].

di Biase L, Munhoz RP. Deep brain stimulation for the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2016 Sep. 16 (9):1067-78. [Medline].

Volkmann J. Is surgical treatment an option for chorea-acanthocytosis? In: Danek A, ed. Neuroacanthocytosis Syndromes. Springer. 2005.

Burbaud P. Deep brain stimulation in neuroacanthocytosis. Mov Disord. 2005. 20:1681-1682.

Beal MF, Hantraye P. Novel therapies in the search for a cure for Huntington’s disease. Proc Natl Acad Sci U S A. 2001 Jan 2. 98(1):3-4. [Medline].

Robinson D, Smith M, Reddy R. Neuroacanthocytosis. Am J Psychiatry. 2004 Sep. 161(9):1716. [Medline].

Habermeyer B, Fuhr P. Obsessive-compulsive disorders due to neuroacanthocytosis treated with citalopram. Pharmacopsychiatry. 2007 Mar. 40(2):87. [Medline].

Vázquez MJ, Martínez MC. Electroconvulsive Therapy in Neuroacanthocytosis or McLeod Syndrome. J ECT. 2008 Nov 7. [Medline].

Akamatsu K, Sakaue H, Tada K, et al. A case report of abetalipoproteinemia (Bassen-Kornzweig syndrome)–the first case in Japan. Jpn J Med. 1983 Aug. 22(3):231-6. [Medline].

Al-Asmi A, Jansen AC, Badhwar A, et al. Familial temporal lobe epilepsy as a presenting feature of choreoacanthocytosis. Epilepsia. 2005 Aug. 46(8):1256-63. [Medline].

Alonso ME, Teixeira F, Jimenez G, Escobar A. Chorea-acanthocytosis: report of a family and neuropathological study of two cases. Can J Neurol Sci. 1989 Nov. 16(4):426-31. [Medline].

Andermann E, Jansen A, Andermann F. French-Canadian chorea-acanthocytosis. Mov Disord. 2005. 20:1678.

Arimura H, Kuriyama M, Higuchi I, et al. [Paroxysmal dystonic choreoathetosis with chronic hemolytic anemia and morphologically abnormal erythrocytes]. Rinsho Shinkeigaku. 1995 Jan. 35(1):29-33. [Medline].

Bansal I, Jeon HR, Hui SR, Calhoun BW, Manning DW, Kelly TJ. Transfusion support for a patient with McLeod phenotype without chronic granulomatous disease and with antibodies to Kx and Km. Vox Sang. 2008 Apr. 94(3):216-20. [Medline].

Beal MF. In: Danek A, ed. Neuroacanthocytosis Syndromes. Springer; 2005.

Bharucha EP, Bharucha NE. Choreo-acanthocytosis. J Neurol Sci. 1989 Feb. 89(2-3):135-9. [Medline].

Bostantjopoulou S, Katsarou Z, Kazis A, Vadikolia C. Neuroacanthocytosis presenting as parkinsonism. Mov Disord. 2000 Nov. 15(6):1271-3. [Medline].

Bramanti P, Ricci RM, Candela L, et al. Sleep spindles in amyotrophic chorea-acanthocytosis disease. Acta Neurol (Napoli). 1987 Jun. 9(3):191-8. [Medline].

Burbaud P, Rougier A, Ferrer X, et al. Improvement of severe trunk spasms by bilateral high-frequency stimulation of the motor thalamus in a patient with chorea-acanthocytosis. Mov Disord. 2002 Jan. 17(1):204-7. [Medline].

Burbaud P, Vital A, Rougier A, et al. Minimal tissue damage after stimulation of the motor thalamus in a case of chorea-acanthocytosis. Neurology. 2002 Dec 24. 59(12):1982-4. [Medline].

Cavalli G, de Gregorio C, Nicosia S, et al. [Cardiac involvement in familial amytrophic chorea with acantocytosis: description of two new clinical cases]. Ann Ital Med Int. 1995 Oct-Dec. 10(4):249-52. [Medline].

Chorea-acanthocytosis: report of two Brazilian cases.

Clapéron A, Hattab C, Armand V, Trottier S, Bertrand O, Ouimet T. The Kell and XK proteins of the Kell blood group are not co-expressed in the central nervous system. Brain Res. 2007 May 25. 1147:12-24. [Medline].

Danek A, Dobson-Stone C, Velayos-Baeza A. The phenotype of chorea-acanthocytosis: a review of 106 patients with VPS13A mutations. Mov Disord. 2005. 20:1678.

Danek A, Jung HH, Melone MA, et al. Neuroacanthocytosis: new developments in a neglected group of dementing disorders. J Neurol Sci. 2005 Mar 15. 229-230:171-86. [Medline].

Danek A, Uttner I, Vogl T, et al. Cerebral involvement in McLeod syndrome. Neurology. 1994 Jan. 44(1):117-20. [Medline].

Dobson-Stone C. The spectrum of mutations and possible function of the CHAC gene In: Danek A, ed. Neuoracanthocytosis Syndromes. Springer. 2005.

Faillace RT, Kingston WJ, Nanda NC, Griggs RC. Cardiomyopathy associated with the syndrome of amyotrophic chorea and acanthocytosis. Ann Intern Med. 1982 May. 96(5):616-7. [Medline].

Ferrer X, Julien J, Vital C, et al. [Choreo-acanthocytosis]. Rev Neurol (Paris). 1990. 146(12):739-45. [Medline].

Gil-Nagel A, Morlan L, Balseiro J, et al. [Neuro-acanthocytosis with associated myopathy. A case report]. Neurologia. 1994 Apr. 9(4):165-8. [Medline].

Gross KB, Skrivanek JA, Emeson EE. Ganglioside abnormality in amyotrophic chorea with acanthocytosis. Lancet. 1982 Oct 2. 2(8301):772. [Medline].

Halliday W. The nosology of Hallervorden-spatz disease. J Neurol Sci. 1995 Dec. 134 Suppl:84-91. [Medline].

Hardie RJ. Acanthocytosis and neurological impairment–a review. Q J Med. 1989 Apr. 71(264):291-306. [Medline].

Hardie RJ, Pullon HW, Harding AE, et al. Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain. 1991 Feb. 114 ( Pt 1A):13-49. [Medline].

Hashimoto T, Nakadai A, Fujimori N, Yanagisawa N. [A case of “chorea with acanthocytosis and neuropathy” (chorea-acanthocytosis) with parkinsonism without areflexia]. Rinsho Shinkeigaku. 1987 Jan. 27(1):88-93. [Medline].

Hewer E, Danek A, Schoser BG, Miranda M, Reichard R, Castiglioni C. McLeod myopathy revisited: more neurogenic and less benign. Brain. 2007 Dec. 130(Pt 12):3285-96. [Medline].

Higgins JJ, Patterson MC, Papadopoulos NM, et al. Hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP syndrome). Neurology. 1992 Jan. 42(1):194-8. [Medline].

Hirayama M, Hamano T, Shiratori M, et al. Chorea-acanthocytosis with polyclonal antibodies to ganglioside GM1. J Neurol Sci. 1997 Oct 3. 151(1):23-4. [Medline].

Iwata M, Fuse S, Sakuta M, Toyokura Y. Neuropathological study of chorea-acanthocytosis. Jpn J Med. 1984 May. 23(2):118-22. [Medline].

Katsube T, Shimono T, Ashikaga R, Hosono M, Kitagaki H, Murakami T. Demonstration of Cerebellar Atrophy in Neuroacanthocytosis of 2 Siblings. AJNR Am J Neuroradiol. 2008 Oct 22. [Medline].

Kohler B. [Hallervorden-Spatz syndrome with acanthocytosis]. Monatsschr Kinderheilkd. 1989 Sep. 137(9):616-9. [Medline].

Kurano Y, Nakamura M, Ichiba M, Matsuda M, Mizuno E, Kato M. Chorein deficiency leads to upregulation of gephyrin and GABA(A) receptor. Biochem Biophys Res Commun. 2006 Dec 15. 351(2):438-42. [Medline].

Kuroiwa Y, Ohnishi A, Sato Y, Kanazawa I. Chorea acanthocytosis: clinical pathological and biochemical aspects. Int J Neurol. 1984. 18:64-74. [Medline].

Kutcher JS, Kahn MJ, Andersson HC, Foundas AL. Neuroacanthocytosis masquerading as Huntington’s disease: CT/MRI findings. J Neuroimaging. 1999 Jul. 9(3):187-9. [Medline].

Larget-Piet L, Pouplard F. [Ataxia-areflexia-familial steatorrhea without abetalipoproteinemia or acanthocytosis]. J Genet Hum. 1981 Sep. 29(3):249-51. [Medline].

Limos LC, Ohnishi A, Sakai T, et al. “Myopathic” changes in chorea-acanthocytosis. Clinical and histopathological studies. J Neurol Sci. 1982 Jul. 55(1):49-58. [Medline].

Lin FC, Wei LJ, Shih PY. Effect of levetiracetam on truncal tic in neuroacanthocytosis. Acta Neurol Taiwan. 2006 Mar. 15(1):38-42. [Medline].

Luckenbach MW, Green WR, Miller NR, et al. Ocular clinicopathologic correlation of Hallervorden-Spatz syndrome with acanthocytosis and pigmentary retinopathy. Am J Ophthalmol. 1983 Mar. 95(3):369-82. [Medline].

Lupo I, Aragona F, Fierro B, et al. Choreo-acanthocytosis with myopathy. Report of a case. Acta Neurol (Napoli). 1987 Oct-Dec. 9(5-6):334-8. [Medline].

Malandrini A, Fabrizi GM, Truschi F, et al. Atypical McLeod syndrome manifested as X-linked chorea-acanthocytosis, neuromyopathy and dilated cardiomyopathy: report of a family. J Neurol Sci. 1994 Jun. 124(1):89-94. [Medline].

Marson AM, Bucciantini E, Gentile E, Geda C. Neuroacanthocytosis: clinical, radiological, and neurophysiological findings in an Italian family. Neurol Sci. 2003 Oct. 24(3):188-9. [Medline].

Miranda M, Campero M, Tenhamm E, Villagra R. [Neuroacanthocytosis: report of 3 cases]. Rev Med Chil. 1993 Feb. 121(2):176-9. [Medline].

Miranda M, Castiglioni C, Frey BM, Hergersberg M, Danek A, Jung HH. Phenotypic variability of a distinct deletion in McLeod syndrome. Mov Disord. 2007 Jul 15. 22(9):1358-61. [Medline].

Mukoyama M, Kazui H, Sunohara N, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes with acanthocytosis: a clinicopathological study of a unique case. J Neurol. 1986 Aug. 233(4):228-32. [Medline].

Müller-Vahl KR, Berding G, Emrich HM, Peschel T. Chorea-acanthocytosis in monozygotic twins: clinical findings and neuropathological changes as detected by diffusion tensor imaging, FDG-PET and (123)I-beta-CIT-SPECT. J Neurol. 2007 Aug. 254(8):1081-8. [Medline].

Nielsen SM, Temlett JA. Neuro-acanthocytosis–a rare cause of chorea. S Afr Med J. 1997 Jul. 87(7):897-8. [Medline].

Nihashi H, Yoshida M. [Cognitive function in patients with parkinsonism–in relationship with frontal lobe symptoms]. No To Shinkei. 1988 Mar. 40(3):261-6. [Medline].

Oechslin E, Kaup D, Jenni R, Jung HH. Cardiac abnormalities in McLeod syndrome. Int J Cardiol. 2007 Nov 26. [Medline].

Oechsner M, Buchert R, Beyer W, Danek A. Reduction of striatal glucose metabolism in McLeod choreoacanthocytosis. J Neurol Neurosurg Psychiatry. 2001 Apr. 70(4):517-20. [Medline]. [Full Text].

Ogawa T, Seki H, Okita N, et al. [A case of chorea-acanthocytosis associated with low glycohemoglobin A1c]. Rinsho Shinkeigaku. 1993 Mar. 33(3):344-6. [Medline].

Ohnishi A, Sato Y, Nagara H, et al. Neurogenic muscular atrophy and low density of large myelinated fibres of sural nerve in chorea-acanthocytosis. J Neurol Neurosurg Psychiatry. 1981 Jul. 44(7):645-8. [Medline].

Orlacchio A, Calabresi P, Rum A, Tarzia A, Salvati AM, Kawarai T, et al. Neuroacanthocytosis associated with a defect of the 4.1R membrane protein. BMC Neurol. 2007 Feb 13. 7:4. [Medline].

Orrell RW, Amrolia PJ, Heald A, et al. Acanthocytosis, retinitis pigmentosa, and pallidal degeneration: a report of three patients, including the second reported case with hypoprebetalipoproteinemia (HARP syndrome). Neurology. 1995 Mar. 45(3 Pt 1):487-92. [Medline].

Parhofer KG, Richter WO, Stiess W, Schwandt P. [Acanthocytosis, short stature and disordered deep sensation in a 26-year-old patient]. Internist (Berl). 1989 Jun. 30(6):382-5. [Medline].

Pisani A, Diomedi M, Rum A, Cianciulli P, Floris R, Orlacchio A, et al. Acanthocytosis as a predisposing factor for non-ketotic hyperglycaemia induced chorea-ballism. J Neurol Neurosurg Psychiatry. 2005 Dec. 76(12):1717-9. [Medline].

Rubio JP, Danek A, Stone C, et al. Chorea-acanthocytosis: genetic linkage to chromosome 9q21. Am J Hum Genet. 1997 Oct. 61(4):899-908. [Medline].

Ruiz-Sandoval JL, García-Navarro V, Chiquete E, Dobson-Stone C, Monaco AP, Alvarez-Palazuelos LE, et al. Choreoacanthocytosis in a Mexican family. Arch Neurol. 2007 Nov. 64(11):1661-4. [Medline].

Saggese G, Baroncelli GI, Bertelloni S, et al. [Chronic granulomatous disease and McLeod phenotype. Description of a case]. Minerva Pediatr. 1990 Apr. 42(4):151-6. [Medline].

Saiki S, Sakai K, Murata KY, Saiki M, Nakanishi M, Kitagawa Y, et al. Primary skeletal muscle involvement in chorea-acanthocytosis. Mov Disord. 2007 Apr 30. 22(6):848-52. [Medline].

Sano A. [Hereditary chorea–update]. Rinsho Shinkeigaku. 2004 Nov. 44(11):932-4. [Medline].

Scheid R, Bader B, Ott DV, Merkenschlager A, Danek A. Development of mesial temporal lobe epilepsy in chorea-acanthocytosis. Neurology. 2009 Oct 27. 73(17):1419-22. [Medline].

Schneider SA, Aggarwal A, Bhatt M, Dupont E, Tisch S, Limousin P. Severe tongue protrusion dystonia: clinical syndromes and possible treatment. Neurology. 2006 Sep 26. 67(6):940-3. [Medline].

Senda Y, Koike Y, Sugimura K, et al. [Chorea-acanthocytosis with catecholamine abnormality and orthostatic hypotension–a case report]. Rinsho Shinkeigaku. 1987 Jul. 27(7):898-903. [Medline].

Serra S, Arena A, Xerra A, et al. Amyotrophic choreoacanthocytosis: is it really a very rare disease?. Ital J Neurol Sci. 1986 Oct. 7(5):521-4. [Medline].

Serra S, Xerra A, Arena A. Amyotrophic choreo-acanthocytosis: a new observation in southern Europe. Acta Neurol Scand. 1986 May. 73(5):481-6. [Medline].

Shah JR, Patkar DP, Kamat RN. A case of McLeod phenotype of neuroacanthocytosis brain MR features and literature review. Neuroradiol J. 2013 Feb. 26(1):21-6. [Medline].

Sobue G, Mukai E, Fujii K, et al. Peripheral nerve involvement in familial chorea-acanthocytosis. J Neurol Sci. 1986 Dec. 76(2-3):347-56. [Medline].

Sotaniemi KA. Chorea-acanthocytosis. Neurological disease with acanthocytosis. Acta Neurol Scand. 1983 Jul. 68(1):53-6. [Medline].

Spencer SE, Walker FO, Moore SA. Chorea-amyotrophy with chronic hemolytic anemia: a variant of chorea-amyotrophy with acanthocytosis. Neurology. 1987 Apr. 37(4):645-9. [Medline].

Spitz MC, Jankovic J, Killian JM. Familial tic disorder, parkinsonism, motor neuron disease, and acanthocytosis: a new syndrome. Neurology. 1985 Mar. 35(3):366-70. [Medline].

Sugihara R, Ueyama H, Fujimoto S, et al. [A case of McLeod syndrome]. Rinsho Shinkeigaku. 1998 Oct-Nov. 38(10-11):915-9. [Medline].

Swash M, Schwartz MS, Carter ND, et al. Benign X-linked myopathy with acanthocytes (McLeod syndrome). Its relationship to X-linked muscular dystrophy. Brain. 1983 Sep. 106 (Pt 3):717-33. [Medline].

Takahashi Y, Kojima T, Atsumi Y, et al. [Case of chorea-acanthocytosis with various psychotic symptoms]. Seishin Shinkeigaku Zasshi. 1983. 85(8):457-72. [Medline].

Takashima H, Sakai T, Iwashita H, et al. A family of McLeod syndrome, masquerading as chorea-acanthocytosis. J Neurol Sci. 1994 Jun. 124(1):56-60. [Medline].

Terao S, Sobue G, Takahashi M, et al. [Disturbance of hypothalamic-pituitary hormone secretion in familial chorea-acanthocytosis]. No To Shinkei. 1995 Jan. 47(1):57-61. [Medline].

Tiftikcioglu BI, Dericioglu N, Saygi S. Focal seizures originating from the left temporal lobe in a case with chorea-acanthocytosis. Clin EEG Neurosci. 2006 Jan. 37(1):46-9. [Medline].

Tiftikcioglu BI, Dericioglu N, Saygi S. Focal seizures originating from the left temporal lobe in a case with chorea-acanthocytosis. Clin EEG Neurosci. 2006 Jan. 37(1):46-9. [Medline].

Tsai CH, Chen RS, Chang HC, et al. Acanthocytosis and spinocerebellar degeneration: a new association?. Mov Disord. 1997 May. 12(3):456-9. [Medline].

Tschopp L, Raina G, Salazar Z, Micheli F. Neuroacanthocytosis and carbamazepine responsive paroxysmal dyskinesias. Parkinsonism Relat Disord. 2008. 14(5):440-2. [Medline].

Villegas A, Moscat J, Vazquez A, et al. A new family with hereditary choreo-acanthocytosis. Acta Haematol. 1987. 77(4):215-9. [Medline].

Walker RH, Danek A, Dobson-Stone C, et al. Developments in neuroacanthocytosis: expanding the spectrum of choreatic syndromes. Mov Disord. 2006 Nov. 21(11):1794-805. [Medline].

Wild EJ, Tabrizi SJ. The differential diagnosis of chorea. Pract Neurol. 2007 Nov. 7(6):360-73. [Medline].

Witt TN, Danek A, Reiter M, et al. McLeod syndrome: a distinct form of neuroacanthocytosis. Report of two cases and literature review with emphasis on neuromuscular manifestations. J Neurol. 1992 Jul. 239(6):302-6. [Medline].

Woodruff RK, Wiley JS, Bell WR, et al. Acanthocytosis and haemolytic anaemia due to the McLeod blood group. Aust N Z J Med. 1981 Apr. 11(2):184-7. [Medline].

Zyskowski LP, Bunch TW, Hoagland HC, et al. Mcleod syndrome (hemolysis, acanthocytosis, and increased serum creatine kinase): potential confusion with polymyositis. Arthritis Rheum. 1983 Jun. 26(6):806-8. [Medline].

Kenneth B V Gross, MD Founder, Owner, Fusion Clinical Multimedia, Inc, Division of Neurology, Fusion Clinical Multimedia Educational Center

Kenneth B V Gross, MD is a member of the following medical societies: American Academy of Neurology

Disclosure: Nothing to disclose.

Nicholas Lorenzo, MD, MHA, CPE Co-Founder and Former Chief Publishing Officer, eMedicine and eMedicine Health, Founding Editor-in-Chief, eMedicine Neurology; Founder and Former Chairman and CEO, Pearlsreview; Founder and CEO/CMO, PHLT Consultants; Chief Medical Officer, MeMD Inc

Nicholas Lorenzo, MD, MHA, CPE is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Association for Physician Leadership

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Nestor Galvez-Jimenez, MD, MSc, MHA The Pauline M Braathen Endowed Chair in Neurology, Chairman, Department of Neurology, Program Director, Movement Disorders, Department of Neurology, Division of Medicine, Cleveland Clinic Florida

Nestor Galvez-Jimenez, MD, MSc, MHA is a member of the following medical societies: American Academy of Neurology, American College of Physicians, International Parkinson and Movement Disorder Society

Disclosure: Nothing to disclose.

Selim R Benbadis, MD Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida Morsani College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, American Medical Association

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Acorda, Livanova, Eisai, Greenwich, Lundbeck, Neuropace, Sunovion, Upsher-Smith.<br/>Serve(d) as a speaker or a member of a speakers bureau for: Livanova, Eisai, Greenwich, Lundbeck, Neuropace, Sunovion.<br/>Received research grant from: Acorda, Livanova, Greenwich, Lundbeck, Sepracor, Sunovion, UCB, Upsher-Smith.

Roberta J Seidman, MD Associate Professor of Clinical Pathology, Stony Brook University; Director of Neuropathology, Department of Pathology, Stony Brook University Medical Center

Roberta J Seidman, MD is a member of the following medical societies: American Academy of Neurology, Suffolk County Society of Pathologists, New York Association of Neuropathologists (The Neuroplex), American Association of Neuropathologists

Disclosure: Nothing to disclose.

Neuroacanthocytosis Syndromes

Research & References of Neuroacanthocytosis Syndromes|A&C Accounting And Tax Services